Unimarck Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 17-11-2024
- Paid Up Capital ₹ 1.79 Cr
as on 17-11-2024
- Company Age 40 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 22.50 Cr
as on 17-11-2024
- Satisfied Charges ₹ 36.15 Cr
as on 17-11-2024
- Revenue -5.00%
(FY 2023)
- Profit -176.52%
(FY 2023)
- Ebitda -60.96%
(FY 2023)
- Net Worth -10.95%
(FY 2023)
- Total Assets -9.33%
(FY 2023)
About Unimarck Pharma (India)
The Corporate was formerly known as Unimarck Pharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.79 Cr.
The company currently has active open charges totaling ₹22.50 Cr. The company has closed loans amounting to ₹36.15 Cr, as per Ministry of Corporate Affairs (MCA) records.
Gagandeep Bhatia, Mandeep Singh, Harleen Bhatia, and One other member serve as directors at the Company.
- CIN/LLPIN
U24232CH1984PLC005768
- Company No.
005768
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
12 Mar 1984
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- LocationUt, Chandigarh
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Unimarck Pharma (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mandeep Singh  | Managing Director | 03-Dec-2015 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Gagandeep Bhatia | Whole-Time Director | 10-Aug-2000 | Current |
| Harleen Bhatia | Director | 01-Apr-2023 | Current |
| Harsh Bhatia | Whole-Time Director | 12-Mar-1984 | Current |
Financial Performance of Unimarck Pharma (India).
Unimarck Pharma (India) Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 5% decrease. The company also saw a substantial fall in profitability, with a 176.52% decrease in profit. The company's net worth observed a substantial decline by a decrease of 10.95%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unimarck Pharma (India)?
In 2023, Unimarck Pharma (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Teriot Pharmaceuticals Private LimitedActive 24 years 10 monthsMandeep Singh and Harleen Bhatia are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 01 Jul 2023 | ₹1.59 M | Open |
Hdfc Bank Limited Creation Date: 10 Sep 2021 | ₹8.50 M | Open |
Others Creation Date: 10 May 2017 | ₹13.26 Cr | Open |
How Many Employees Work at Unimarck Pharma (India)?
Unimarck Pharma (India) has a workforce of 409 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unimarck Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unimarck Pharma (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
